Clinical Trial Update: Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Paclitaxel for recurrent or refractory head and neck cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Theradex | Conditions: Head and Neck Cancer | Phase 2 | Status: UNKNOWN